Vasopressors are drugs that tighten blood vessels to raise dangerously low blood pressure, most often used in intensive care when someone is in shock. The defining feature of these medications is vasoconstriction: they act on receptors in the smooth muscle lining of arteries to squeeze those vessels tighter, which drives blood pressure up and pushes blood toward vital organs. The most common vasopressor by far is norepinephrine, a synthetic version of a hormone your body already makes. But the category includes several agents with overlapping and sometimes very different mechanisms, and choosing among them is less straightforward than it might seem.
How Vasopressors Raise Blood Pressure
Blood pressure depends on two things: how forcefully the heart pumps and how tightly the blood vessels resist flow. Vasopressors work mainly on the second part. Most of them activate alpha-1 adrenergic receptors on the smooth muscle cells that wrap around arteries. When those receptors are switched on, calcium floods into the muscle cells, causing them to contract and narrow the vessel. The result is higher resistance in the vascular tree and, consequently, higher blood pressure. The body’s own version of this system uses norepinephrine and epinephrine, released by the adrenal glands and sympathetic nerves, to regulate vascular tone moment to moment.1PubMed. Relationship between alpha(1)-adrenergic receptor-induced contraction and extracellular signal-regulated kinase activation in the bovine inferior alveolar artery
The density of alpha-1 receptors on a given blood vessel determines how sensitive it is to these signals. Lab studies show that smooth muscle cells engineered to carry more alpha-1 receptors contract faster and respond to lower doses of stimulation, with contraction speed roughly doubling when receptor density is increased.2PubMed. Impact of alpha1-adrenoceptor expression on contractile properties of vascular smooth muscle cells This explains why vasopressor drugs don’t work equally well in every patient or every tissue bed: the number and availability of those receptors vary with genetics, disease state, and which organ’s vessels you’re looking at.
Vasopressors Versus Inotropes
People sometimes use “vasopressor” and “inotrope” interchangeably, but they describe different actions. An inotrope increases the squeezing force of the heart muscle, boosting cardiac output. A vasopressor constricts blood vessels to raise pressure. Some drugs do both. Norepinephrine and epinephrine are sometimes called “inopressors” because they raise blood pressure through vasoconstriction while also giving the heart a modest contractile boost. Dobutamine, milrinone, and levosimendan are primarily inotropes and actually dilate blood vessels while strengthening the heartbeat, earning them the label “inodilators.” Pure vasopressors like phenylephrine and vasopressin tighten vessels without meaningfully strengthening the heart.3American Heart Journal Plus: Cardiology Research and Practice. The current use of vasoactive agents in cardiogenic shock related to myocardial infarction and acute decompensated heart failure
The distinction matters in practice. A patient whose blood pressure is low because their heart is failing needs an inotrope to help the pump. A patient whose blood pressure is low because their vessels are too relaxed, as happens in septic shock, needs a vasopressor. Many critically ill patients need some combination of both, and the ICU team adjusts the cocktail based on real-time measurements of cardiac output, vascular resistance, and organ perfusion.
Why Norepinephrine Is First Choice in Septic Shock
For decades, the question of whether norepinephrine or dopamine should be the go-to vasopressor in sepsis generated genuine debate. That argument is now largely settled. Multiple meta-analyses of randomized trials found that dopamine is associated with a higher risk of death and more than double the rate of abnormal heart rhythms compared to norepinephrine.4PubMed. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis A separate systematic review confirmed the survival advantage, finding roughly a 9 percent relative reduction in mortality with norepinephrine.5PubMed. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials A third large review reached the same conclusion and explicitly recommended norepinephrine as the first-line vasopressor in septic shock based on survival benefit, a better hemodynamic profile, and fewer adverse events.6PLoS ONE. Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis
Dopamine hasn’t vanished from use entirely. It has dose-dependent behavior: at very low infusion rates it mainly dilates kidney and gut blood vessels, at moderate doses it strengthens the heartbeat, and only at high doses does it act as a potent vasoconstrictor. That graded profile still has niche roles, but the arrhythmia risk makes it a poor default choice when the primary goal is raising blood pressure in sepsis.
When Norepinephrine Isn’t Enough
In severe septic shock, some patients need escalating doses of norepinephrine that carry their own dangers. High catecholamine doses can cause heart damage, dangerous rhythm disturbances, and reduced blood flow to the fingers and toes. This is where vasopressin enters the picture. Vasopressin is a peptide hormone that constricts blood vessels through a completely different receptor system, the V1 receptor, rather than the alpha-1 adrenergic pathway. Up to a third of patients with septic shock become deficient in their own vasopressin, which contributes to the refractory drop in blood pressure.7PubMed Central. Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?
Adding low-dose vasopressin allows clinicians to cut back on norepinephrine dramatically. In a randomized trial, patients who received vasopressin saw their norepinephrine requirement drop from a median of 25 micrograms per minute to about 5 within four hours, a roughly 80 percent reduction. Patients who stayed on norepinephrine alone barely budged from their starting dose.8Anesthesiology. Beneficial Effects of Short-term Vasopressin Infusion during Severe Septic Shock This “norepinephrine-sparing” strategy, sometimes called decatecholaminization, is now a core part of managing difficult shock.
Angiotensin II as a Rescue Option
For patients who remain in shock despite norepinephrine and vasopressin, options used to be extremely limited. A relatively recent addition is synthetic angiotensin II, approved after a pivotal trial showed it was dramatically more effective than placebo at raising blood pressure to target. About 70 percent of patients receiving angiotensin II reached the blood pressure goal, compared to roughly 23 percent on placebo.9PubMed. Angiotensin II for the Treatment of Vasodilatory Shock Angiotensin II works through yet another receptor pathway, making it a genuinely different tool rather than a variation on the catecholamine theme.
Case reports have documented angiotensin II rescuing patients from vasopressor-refractory shock in situations ranging from pediatric sepsis to drug overdose. In one dramatic case, a patient in profound shock from a massive clozapine ingestion, an antipsychotic that blocks the very alpha receptors norepinephrine relies on, was unresponsive to extremely high doses of conventional vasopressors. After angiotensin II was started, all other vasopressors were weaned off within 18 hours.10PubMed Central. Vasopressor-Refractory Shock From Clozapine Overdose Treated With Synthetic Angiotensin II Infusion Pediatric reports show similar promise, with rapid blood pressure improvement and catecholamine reduction.11PubMed Central. Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients Whether angiotensin II improves survival on a population level is still being worked out, but its ability to raise pressure when nothing else will has carved out a clear niche.
What Blood Pressure Target Are Clinicians Aiming For?
The standard initial target in septic shock is a mean arterial pressure (MAP) of at least 65 mmHg. A large multicenter trial compared a higher target of 80 to 85 mmHg against 65 to 70 mmHg in nearly 800 patients and found no difference in mortality at 28 or 90 days.12PubMed. High versus low blood-pressure target in patients with septic shock Pushing for a higher number simply meant more vasopressor exposure without a payoff in lives saved.
There’s one important exception. Patients who had chronic high blood pressure before they got sick seem to benefit from a somewhat higher target, around 75 to 85 mmHg. Their kidneys, adapted to operating at higher pressures, are more vulnerable to acute injury when MAP sits at 65.13PubMed Central. Optimizing mean arterial pressure in septic shock: a critical reappraisal of the literature Current reviews acknowledge this tension and recommend an individualized approach, weighing the severity of shock, pre-existing conditions, and how the patient responds to initial resuscitation.14PubMed Central. Optimizing Mean Arterial Pressure Targets for Septic Shock Patients With Chronic Hypertension: A Narrative Review
Pressure targets differ in other types of shock. After acute spinal cord injury, for example, guidelines suggest a considerably higher MAP floor of 75 to 80 mmHg maintained for three to seven days, because the damaged spinal cord needs robust perfusion pressure to limit secondary injury. Norepinephrine is still the usual first choice in that context, though dopamine and phenylephrine each have situational roles.15PubMed Central. Vasopressor Use in Acute Spinal Cord Injury: Current Evidence and Clinical Implications
Giving Vasopressors Through a Peripheral IV
Traditionally, vasopressors were given only through a central line, a catheter threaded into a large vein near the heart. Placing a central line takes time and carries its own risks, including infection and punctured lungs. Over the past decade, evidence has accumulated that peripheral IVs can safely deliver vasopressors in many situations, especially for short durations or moderate doses while a central line is being placed.
A systematic review and meta-analysis of over 16,000 adult patients receiving vasopressors through a peripheral IV found an overall adverse event rate of about 1.8 percent.16PubMed Central. Adverse events associated with administration of vasopressor medications through a peripheral intravenous catheter: a systematic review and meta-analysis A more recent analysis broke down the specific complications and reported extravasation (the drug leaking out of the vein into surrounding tissue) at about 1.4 percent, thrombosis at a similar rate, and infection below 1 percent.17PubMed Central. Extravasation, thrombosis, and infection with vasopressor infusion through peripheral intravenous catheters: a systematic review and meta-analysis Many hospitals now have specific peripheral vasopressor protocols that dictate IV size, site checks, and concentration limits. Interestingly, a meta-analysis comparing hospitals with formal protocols to those without found similar extravasation rates, suggesting that the inherent risk may be low enough that protocols serve mainly as a safety net rather than a dramatic risk reducer.18PubMed. The effect of peripheral vasopressor protocols on extravasation rates: A systematic review and meta-analysis
What Happens When Vasopressors Leak
Extravasation is the complication that gets the most attention with peripheral vasopressor delivery. Because these drugs powerfully constrict small blood vessels, leaking into surrounding tissue can cut off local blood flow and cause tissue death. The standard antidote is phentolamine, an alpha-receptor blocker injected into the affected area to counteract the vasoconstriction.19PubMed Central. Alternative Pharmacological Management of Vasopressor Extravasation in the Absence of Phentolamine In animal models, subcutaneous phentolamine injection appears effective at preventing tissue injury when given promptly.20PubMed. The use of phentolamine in the prevention of dopamine-induced tissue extravasation
The catch is that phentolamine is frequently unavailable, either because of drug shortages or because hospitals don’t stock it routinely. This has spurred interest in alternatives like nitroglycerin paste and terbutaline, though evidence for these remains thin. In practice, the most important intervention is early recognition: nursing staff monitoring IV sites closely can catch extravasation before significant tissue damage occurs.
The Danger of Prolonged High Doses
All vasopressors can harm the extremities if used at high doses for extended periods. The same vasoconstriction that saves the brain and kidneys by redirecting blood centrally can starve the fingers, toes, and nose of blood flow. In severe cases this progresses to symmetrical peripheral gangrene, a devastating complication where tissue in the hands and feet dies and may require amputation.
A study of risk factors found that patients who developed peripheral gangrene were receiving vastly higher vasopressor doses than those who didn’t. Dopamine doses in the gangrene group averaged nearly nine times the accepted upper limit, and norepinephrine doses were nearly 48 times higher. Peak dose appeared to be a more important driver than total duration of use.21PubMed Central. Risk Factors of Vasopressor-Induced Symmetrical Peripheral Gangrene This is a key reason ICU teams work so hard to keep vasopressor doses as low as possible by adding agents from different receptor classes and treating the underlying cause of shock aggressively.
Why Acidosis Makes Vasopressors Work Poorly
Clinicians have long observed that patients who are deeply acidotic, with blood pH well below normal, often respond poorly to vasopressors. Classic animal experiments confirmed this: the pressor response to epinephrine, norepinephrine, and other sympathomimetics was dramatically blunted during acidosis, and restoring normal pH restored responsiveness.22PubMed Central. Vasopressor agents; influence of acidosis on cardiac and vascular responsiveness
More recent human data refines this picture. An observational study of septic shock patients found that for each 0.1 unit drop in arterial pH below 7.40 at the time vasopressin was started, the odds of responding to vasopressin fell by about 21 percent. Patients who started vasopressin with worse acidosis also needed higher catecholamine doses in the hours afterward.23PubMed Central. Association of Arterial pH With Hemodynamic Response to Vasopressin in Patients With Septic Shock: An Observational Cohort Study Interestingly, isolated vessel experiments with human mammary arteries didn’t show a statistically significant reduction in the contraction force of epinephrine or norepinephrine even at very low pH levels, though the effect sizes were sometimes large.24PubMed. Effect of severe acidosis on vasoactive effects of epinephrine and norepinephrine in human distal mammary artery This disconnect suggests that the problem in living patients isn’t simply that the drugs can’t make vessels contract. Acidosis probably impairs vasopressor response through broader mechanisms, including changes in receptor signaling and the inflammatory cascade that accompany severe illness. The practical takeaway for ICU teams is that correcting the cause of acidosis is at least as important as turning up the vasopressor dose.
Steroids as a Partner Therapy
Low-dose hydrocortisone has become a common add-on for patients whose shock doesn’t respond adequately to vasopressors alone. Sepsis causes a complex state of vascular unresponsiveness where blood vessels lose their ability to constrict normally despite high circulating levels of catecholamines.25PubMed. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside Corticosteroids help restore vascular sensitivity to catecholamines through several pathways, including suppressing the inflammatory mediators that cause vascular relaxation and upregulating adrenergic receptor expression.
Reviews of recent trial data indicate that low-dose hydrocortisone improves hemodynamic stability and speeds shock reversal in vasopressor-resistant septic shock, with evidence pointing to reduced mortality as well.26PubMed Central. Steroids in the Management of Ionotropic-Resistant Septic Shock: A Comprehensive Review of Efficacy and Outcomes Clinical studies confirm that adding hydrocortisone reduces the daily norepinephrine requirement significantly.27European Journal of Cardiovascular Medicine. Role Of Corticosteroid in Septic Shock- A Study at Tertiary Care Hospital The steroid dose used in this setting is much lower than what most people associate with steroids. It’s meant to replace what the body should be producing under stress, not to suppress the immune system broadly.
The Epinephrine Lactate Puzzle
Epinephrine is sometimes used as a vasopressor, particularly in anaphylaxis and cardiac arrest, and occasionally in septic shock when first-line agents fall short. One of its quirks is that it reliably raises blood lactate levels. In ICU medicine, rising lactate is normally a red flag suggesting that tissues aren’t getting enough oxygen. This creates a confusing signal: is the patient getting worse, or is the drug itself causing the number to climb?
The answer, in most cases, is the drug. Epinephrine stimulates a metabolic pathway in skeletal muscle that generates lactate as a byproduct of revved-up cellular energy production, even when oxygen delivery is perfectly adequate.28PubMed. Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis Case reports have documented large, transient lactate spikes during epinephrine infusion that resolved completely after the drug was stopped, confirming a metabolic effect rather than worsening shock.29PubMed Central. When anaphylactic shock meets epinephrine and blood lactate increases: A case report Clinicians who are aware of this phenomenon can avoid unnecessary panic and escalation of care in response to a lab value that is, in this context, misleading.
Pediatric Vasopressor Use
Children in septic shock present different physiological challenges than adults. Their cardiac output depends more heavily on heart rate than on the volume of each heartbeat, and their vascular tone responds differently to illness. Historically, dopamine was the preferred first-line vasopressor in pediatric sepsis based on older guidelines. Practice has shifted considerably. Survey data from pediatric intensivists across Europe show that norepinephrine is now the first drug started by 60 percent of respondents, with epinephrine used first by about a quarter. Dopamine as a first choice has dropped to around 13 percent.
Despite this shift in practice, the evidence base in children is much thinner than in adults. Most of the landmark trials comparing vasopressors were conducted entirely in adult populations, and extrapolating those results to a six-month-old is uncertain at best. Pediatric-specific randomized trials are difficult to run because the patient population is smaller and the clinical presentations are more heterogeneous. The result is that pediatric vasopressor choice still relies heavily on clinician experience and institutional tradition, with norepinephrine increasingly the default but without the same level of direct trial evidence that exists in adult critical care.